A Review of Emerging and Non-US FDA-Approved Topical Agents for the Treatment of Basal Cell Carcinoma
Document Type
Article
Publication Title
Future Oncology
Abstract
Although surgical therapy continues to be the gold standard for the treatment of basal cell carcinoma given high cure rates and the ability to histologically confirm tumor clearance, there are a number of nonsurgical treatment options that may be considered based on individual tumor characteristics, functional and cosmetic considerations, patient comorbidities and patient preference. Topical 5-fluorouracil 5% cream and imiquimod 5% cream have been US FDA-approved for the treatment of superficial basal cell carcinoma. Additionally, a number of new and emerging topical agents and techniques have been described for the treatment of basal cell carcinoma and will be reviewed herein.
DOI
10.2217/fon-2020-1147
Publication Date
8-2021
Keywords
antibodies, basal cell carcinoma, diclofenac, hedgehog pathway inhibitor, immunotherapy, retinoid, skin cancer, topical, treatment
ISSN
1744-8301
Recommended Citation
Kash N, Silapunt S. A Review of Emerging and Non-US FDA-Approved Topical Agents for the Treatment of Basal Cell Carcinoma. Future Oncology. 2021; 17(23). doi: 10.2217/fon-2020-1147.
